Join David Keller, CMT for a powerful, interactive, and actionable fireside chat on markets in 2026. He will share his analysis of key market trends so far this year – including behind-the-scenes sector rotation, foreign market outperformance, volatility in precious metals, and more. He will also discuss what his technical indicators are showing and how investors and traders can best navigate volatile markets. Plus, he’ll explain what institutional investor-style tactics and strategies you can apply as an individual investor to maximize your portfolio returns.

• Get a roadmap of how he sees the market topping out - and where he expects the next bear market to take us.

• See why Avi believes we are likely coming to the end of a long-term cycle in both the equity and metals markets.

CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose, and provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids and empowering individuals to maintain a long-term recovery.

The S&P 500 recorded a “three-peat” in 2025, or three successive years of double-digit gains. What is the likelihood of scoring a “four peat?” Even though CFRA thinks the bull will remain intact by year-end, it projects increased volatility along with a lower-than-average full-year percentage increase. Why so cautious? Still-high valuations, an elevated Buffett Indicator, a softening jobs market, late-cycle and defensive sector leadership, combined with mid-term elections that typically present formidable headwinds. Offsetting tailwinds include the fourth year of this bull market and double-digit earnings growth expectations, not only for 2026 but also for 2027. Sam Stovall, CFRA’s Chief Investment Strategist, will discuss what the market’s recent rotation implies for investor returns in the year ahead.

A summary of the rapid recent growth in international Critical Mineral requirements and the powerful portfolio effects from investment in a new discovery.

PRC Equity Fund is a Regulation A Fund qualified by the SEC to issue securities to accredited and non-accredited investors. PRC Equity Fund provides upfront capital to acquire and develop student housing near public universities. Working in tandem with its primary customer, Project PRC, it has access to virtually limitless capital through the tax-exempt bond market. Investors participate passively, earning an annualized 10% and participating in a 70% profit share.

In this session, we'll dig into the potential benefits and risks of investing in private companies, especially as publicly traded stocks hover near all-time highs. Viewers will find out how to access some of the hottest pre-IPO companies like SpaceX and OpenAI, as well as how to gain diversified exposure to some of today's fastest-growing, game-changing companies.

This talk will explain what liquid alternative funds are and how they can benefit retail investment portfolios.  It will detail their advantages and disadvantages and the 6-year journey, initiated by the Ontario Securities Commission, up to promulgation (official law) and the 6-7 years since then.  Viewers will also view updated performance information and their efficacy through market crises. 

Small- and mid-cap equities enter 2026 with improving earnings leadership, discounted valuations, and stabilizing business sentiment after several years of lagging performance versus mega-caps.